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Background Prolongation of the QT interval on the electrocardiogram is clinically important due to the association with an
increased risk of sudden cardiac death. A long QT interval may be genetically determined (congenital long QT syn-
drome) or be drug-induced long QT syndrome e.g. caused by pharmaceutical drugs and electrolyte imbalances.
...................................................................................................................................................................................................
Case summary In this report, we describe the case a 54-year-old woman, who presented with syncope. At presentation, the QTc
interval was markedly prolonged, and she was admitted for observation under telemetry. The following day the pa-
tient had experienced a near syncope during an episode of 18 s of Torsade de Pointes (TdP). At the time of TdP,
the potassium level (3.4 mmol/L) was mildly reduced, and the ECG showed a QTc interval of 640 ms. In spite of
correction of hypokalaemia and discontinuation of the possibly LQTS-inducing drug citalopram the QTc duration
remained intermittently prolonged. A transthoracic echocardiogram and a recent coronary angiogram were normal.
The patient received an implantable cardioverter-defibrillator. Subsequent genetic testing identified a heterozygous
KCNE1 p.D85N (c.253G>A) variant, a known QT modifier with a population prevalence of 1.3%.
...................................................................................................................................................................................................
Discussion We conclude that the combination of a commonly prescribed antidepressant, discrete hypokalaemia, and a com-
mon KCNE1 QT modifier may cause severe QTc prolongation and life-threatening arrhythmia.
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Introduction
Prolongation of the QTc interval on electrocardiogram (ECG) is
associated with an increased risk of ventricular arrhythmias and sud-
den cardiac death.1 QTc prolongation results from dysfunction of
cardiac ion channels; predominantly altered function of cardiac potas-
sium (Ikr and Iks) or cardiac sodium channels (Ina) may elicit the
phenotype of the long QT syndrome.2 In the congenital form of long
Learning points
• Patients with a KCNE1 D85N variant should avoid reversible
risk factors for drug-induced long QT syndrome (diLQTS).
• The finding of a KCNE1 D85N variant can be used to deter-
mine whether the relatives share the same increased risk of
diLQTS.
* Corresponding author. Tel: þ45 3868 6674, Email: pmarstrand@hotmail.com. This case report was reviewed by Rami Riziq Yousef Abumuaileq, Tor Biering-Sørensen, Mark
Philip Cassar, Peysh A. Patel, and Christian Fielder Camm.
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QT syndrome (cLQTS), the ion channels are dysfunctional due to
inherited mutations2 but the same ion channels can also be affected
by numerous drugs and hypokalaemia.3 Drug-induced long QT syn-
drome (diLQTS) is mainly caused by drugs affecting the promiscuous
hERG channel.4 However, recent studies have also identified an add-
itional underlying genetic disposition or susceptibility to diLQTS;
30% carry a mutation in the KCNQ1, KCNH2, SCN5A, KCNE1, or
KCNE2 genes.5 These patients can be perceived as having as a subclin-
ical form of cLQTS, which will only be expressed when the Ikr current
is exposed to a blocking agent. The identification of a disease-causing
or a susceptibility inducing mutation may be useful in counselling the
proband and relatives at possible risk.
Timeline
Case presentation
A 54-year-old woman was brought to the emergency department
after a syncope at home. The patient had been cleaning the barbecue
in the garden when she felt ‘hard heart beats’ and passed out without
further warning. The patient had no memory of the incident that had
resulted in a mild head trauma.
Her past medical history was remarkable for deep vein thrombosis
(10 years earlier), ankylosing spondylitis, depression, and a recent
transient ischaemic attack (TIA). Approximately 5 years earlier the
patient had undergone a coronary angiogram following an episode of
chest pains. The angiogram had identified no atheromatosis.
Cardiovascular risk factors encompassed hypertension, well-
controlled hypercholesterolaemia, and depression. The patient had
never smoked and did not have diabetes or a family history of heart
disease or sudden premature death. The physical examination,
including a cardiac and neurological examination, showed no
abnormalities.
At admission, the patient was prescribed the following: citalopram
40 mg/day, adalimumab 40 mg subcutaneously/2 weeks (for ankylos-
ing spondylitis), paracetamol p.n. 1 g max 4 times/day, enalapril
10 mg/day, atorvastatin 40 mg/day, and clopidogrel 75 mg/day.
A CT scan of the cerebrum showed no cerebral damage.
The ECG showed sinus rhythm and QTc interval þ600 ms
(Figure 1A). Blood tests were largely normal [serum: potassium
3.4 mmol/L (ref 3.5–4.6 mmol/L) and magnesium, 1.01 mmol/L (ref
0.71–0.94 mmol/L)]. Haemoglobin, leucocytes, creatinine, sodium,
alanine transaminase, basic phosphatase, and C reactive protein were
within normal ranges. Also, troponin I and D-dimer were not ele-
vated. A transthoracic echocardiography was performed, showing no
abnormalities.
After 1 day of telemetry, an episode of self-terminating Torsade de
Pointes (TdP) lasting 18 s was recorded (Figure 1B). The patient was
conscious during the episode but reported feeling dizzy and that
symptoms were similar to what she had felt before her syncope the
previous day. Empirical treatment with 16 mmol intravenous magne-
sium and 3 g of potassium chloride was immediately given. Serum po-
tassium increased to 3.8 mmol/L on the following day but the QTc
interval remained prolonged (640 ms).
The case was conferred with a psychiatrist, and citalopram was
tapered under simultaneous rapid titration of sertraline to 100 mg/
day. Citalopram was completely discontinued from Day 5. At 1 week
from admission, the QTc duration was within normal range (Figure
1C, QTc 450 ms), but the QTc duration fluctuated and was found
outside normal range at Day 9 (600 ms), before normalization at Day
15 (460 ms). Earlier ECGs were available for evaluation; previous
recordings showed QTc between 440 and 580 ms (Figure 1D).
At this point, it was considered possible that the patient was
afflicted with the congenital long QT syndrome; even though two
known triggers of induced QTc prolongation were present, correc-
tion of these did not clearly normalize QTc duration. In addition, pre-
vious ECG recordings clearly documented intermittent, significant
QTc prolongation over an extended time period. On Day 8 treat-
ment with atenolol 25 mg was initialized. On Day 9, an implantable
cardioverter-defibrillator (VVI-ICD) was implanted. Genetic testing
was ordered and the proband was found to be heterozygote carrier
of the KCNE1 D85N (c.253G>A) variant.
The patient was closely followed the first 6 months after the TdP
episode and seen monthly in the out-patient clinic. Currently, the pa-
tient is scheduled for follow-up with her cardiologist yearly, her ICD
is interrogated in clinic every 6 months and by remote monitoring
every 4 months. In 18 months of follow-up, the ICD has not regis-
tered any arrhythmias.
Discussion
We present a patient with syncope, severe QTc prolongation, and
Torsades de Pointes ventricular tachycardia during treatment with
citalopram. The patient was a heterozygous carrier of a KCNE1
.................................................................................................
Timeline for hospitalization in 2016
Time Event
10 months prior Started citalopram 20 mg/day for
depression
3 months prior
(in hospital for 2 days)
Hospitalised due to dizziness and head-
ache. An MRI identified an ischaemic
lesion in the internal capsule. No
sequelae
Hospitalization, Day 0 Malignant syncope, QTc interval at ad-
mission 490 ms
In hospital, þ1 day QTc interval = 640 ms. 18 s of Torsade
de Pointes. Patient felt dizzy but
remained conscious during the
episode
In hospital, þ3 days Antidepressant was switched from cita-
lopram to the non-QT-prolonging
antidepressant sertraline
In hospital, þ7 days Normalization of QT-interval, QTc =
450 ms
In hospital, þ9 days Implantation of implantable cardi-
overter-defibrillator
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.D85N (c.253G>A) variant. The gene encodes for the b-subunit of
the voltage-gated potassium channels and the D85N (c.253G>A)
variant has been associated with an increase in QTc interval of
8 ms.6 Also, the variant is over-represented in patients with
diLQTS7 and is a known modifier gene in cLQTS, type one.8
Distinguishing between diLQTS and cLQTS is challenging as there
is a significant overlap in the phenotype including QTc duration on
the ECG.5 One study reported that 40% of patients with diLQTS
may have an underlying cLQTS diagnosis.9 When applying the
cLQTS score on our patient, she would receive three points in
total (two points for TdP and one for syncope). Three points
would categorize the patients as having ‘intermediate probability
of cLQTS’.1 However, due to the reversible QT-prolongation,
which normalized after discontinuing citalopram and correction of
mild hypokalaemia, she was considered to have diLQTS.
Citalopram has a half-life of 36 h, and the patient’s QTc interval
was within normal range 4 days (Day 7) after substitution of citalo-
pram with sertraline. Also, we found that on Day 9, the QTc
I
A
B
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
Figure 1 (A) Twelve-lead electrocardiogram on admission showing prolonged QTc interval (QTc =þ600 ms). (B) Telemetry print on Day 2 of ad-
mission showing Torsade de Pointes. (C) Electrocardiogram examples during admission with severely prolonged QTc intervals. (D) Historical elec-
trocardiograms used in the evaluation of the patient.
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interval was prolonged to 600 ms, which suggests that the QT-pro-
longation observed on the ECGs from this patient was not solely
explained by treatment with citalopram. Consequently, we advised
the patient to avoid all QTc prolonging drugs in the future.
According to 2015 ESC guidelines, implantation of an ICD in cases
with drug-related pro-arrhythmia, should rely on an individual
evaluation (Class IIa, Level C).10 Based on the serial ECG findings in
our patient, we remained unassured that her risk of future malig-
nant arrhythmias would be sufficiently controlled solely by avoid-
ing QTc prolonging drugs, therefore, an ICD was implanted. This is
supported by the only recent study with long-term follow-up on
diLQTS patients with ICDs, where they reported that 44% of
patients with an ICD following aborted sudden cardiac death due
to diLQTS received appropriate shocks during a mean follow-up
of 84 ± 55 months.11 In contrast, among patients with cLQTS, only
18–28% of patients with cLQTS experience appropriate shocks by
their ICD.12,13 Though device programming may differ between
studies and account for some of this observed difference, one may
speculate that we at this point only identify the most malignant
subgroup of diLQTS patients since their subsequent risk of ICD
shocks is relatively high.
Different drug classes can cause diLQTS and TdP; a frequently
updated online tool is available for risk assessment by drug type for
physicians and patients.14 Citalopram is listed in the category of high-
est risk (‘Known Risk of TdP’). Moreover, a Danish study associated
citalopram with a 30% increase in risk for out-of-hospital cardiac ar-
rest.15 This data supported our concern that citalopram may have eli-
cited the arrhythmias observed in this patient. The genetic test result
supported the notion that the patient was at increased risk of drug-
induced ECG alterations and hereby at risk of malignant arrhythmias.
+1 day +1 day +2 days +3days
+5 days +7 days +9 days +15 days
QTc 640 ms      QTc 640 ms.           QTc 670 ms.
QTc 590 ms.            QTc 450 ms.          QTc 600 ms. QTc 460 ms.
V1
V2
V3
V4
V5
V6
V1
V2
V3
V4
V5
V6
2011     2012 2015 April 2016
QTc 440 ms.                     QTc 570 ms.                QTc 470 ms.                    QTc 580 ms.
V1
V2
V3
V4
V5
V6
II
V1
V2
V3
V4
V5
V6
C
D
Figure 1 Continued.
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However, it should be noted that the minor allele frequency of
KCNE1 D85N (c.253G>A) occurs with an approximate 1.3% percent
frequency in the Danish background population. Also, the patient had
several other risk factors for diLQTS: female sex, age, pre-citalopram
QTc interval in the high-normal range, and a slightly reduced potas-
sium level. The individual contribution of these distinct risk factors is
probably impossible to estimate in the clinical setting. At this point
genetic testing and counselling should be tailored to the individual. In
this family, one could interpret the findings as the proband as carrying
a genetic susceptibility to drug-induced arrhythmias and screen family
members accordingly (Figure 2).
Supplementary material
Supplementary material is available at European Heart Journal - Case
Reports online.
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